STOCKS TELEGRAPH

Tag: VVOS

  • Why VVOS Stock Topping Charts in the Pre Market Today

    Why VVOS Stock Topping Charts in the Pre Market Today

    Vivos Therapeutics Inc. (VVOS), a prominent name in the US stocks market, has been under the spotlight recently. This leading medical technology company has been making waves with its innovative diagnostic and treatment methods for patients grappling with various health conditions.

    Many of these conditions are associated with breathing-related sleep disorders emerging from certain dentofacial abnormalities.

    In the pre-market session today, Vivos Therapeutics Inc. (VVOS) showcased remarkable stock performance, with its price surging to $0.28, reflecting a substantial change of 51.46%.

    This substantial uptick in price was accompanied by robust trading activity, as the trading volume reached a significant 11,390,000 shares. These noteworthy market movements have undoubtedly captured the attention of investors, signaling potential market enthusiasm and heightened anticipation for the trading day ahead.

    Recent Happenings

    October 4, 2023, Vivos Therapeutics has announced forging strategic collaborations and agreements that not only expand its product line but also create promising revenue opportunities.

    The company publicized two key strategic agreements, which are expected to add potentially significant new revenue opportunities for Vivos, as well as airway-focused expertise and potential cost savings for Vivos-trained providers.

    Collaborations with Ormco and On Demand Orthodontist

    One of these collaborations involves Ormco, a division of publicly-traded Envista Holdings Corporation, and On Demand Orthodontist (ODO).

    Ormco, recognized for its exceptional products and customer service, has helped doctors treat more than 20 million patients in over 140 countries. Their Spark™ Clear Aligners are rapidly becoming the go-to clear aligner of choice for orthodontic specialists.

    As part of this agreement, Vivos and Ormco will embark on joint marketing and sales support from each company’s field sales teams. This is expected to facilitate faster treatment times and improved predictability for positive clinical outcomes for Vivos patients using Vivos CARE devices with Spark Aligners.

    The new agreement with ODO, on the other hand, provides a service to Vivos providers featuring direct access and case collaboration with airway-focused orthodontic specialists who are available to help optimize clinical outcomes for Vivos cases.

    The Way Forward for Vivos Therapeutics

    Despite the challenges posed by the larger economic and market environment, Vivos Therapeutics has positioned itself to achieve revenue growth and, ultimately, cash flow positive operations and profitability in the foreseeable future.

    With their innovative, evidence-based technology and a network of trained providers, they remain committed to their core mission of addressing the crisis of sleep apnea and breathing-related sleep issues. This makes Vivos a key player to watch in the US stocks market.

  • Vivos Therapeutics (VVOS) stock gained in the Pre-market; here is why?

    Vivos Therapeutics (VVOS) stock gained in the Pre-market; here is why?

    Vivos Therapeutics (VVOS) stock gained in the pre-market. It was valued at around $2.40, gaining more than 47.23% from the previously closed value. At the end of the last trading session, the stock closed at approximately $1.63. The stock traded volume in the previous trading session was 123K shares.

    Reason for VVOS stock gain

    Vivos Therapeutics (VVOS) announced that its Sleep Apnea Tests had seen significant increases in several key metrics from SleepImage Home.

    The three months ended December 31, 2021, compared to the same period in 2020, observed an 18-fold increase in the number of HSTs given by Vivos trained dentists (known as VIPs). There was a 5.7-fold increase in VIP HST administrators and a 3x increase in average HSTs per VIP.

    This significant improvement in-home sleep testing performance enabled Vivos to restructure its commercial deal with SleepImage. It will lower costs and turn the diagnostic program into a cash cow. Vivos will now lease SleepImage ring recorders to Vivos-trained dentists for a fixed monthly fee that includes diagnostic sleep test reports.

    More than one billion people worldwide and 54 million Americans have sleep apnea, with 80% undiagnosed. Stress, anxiety, and depression can all be caused by sleep apnea. The Vivos System non-surgical treatment protocol addresses dental tissue anomalies and malformations associated with OSA. Instead of requiring lifetime use of CPAP machines or surgical procedures, patients treated with the Vivos System typically finish therapy in 12 to 24 months and rarely require further treatment.

    Effect on the stock

    Vivos Therapeutics (VVOS) was declining, but its announcement of results for the study on sleep apnea lifted it. Investors are investing in its stock, seeing the potential of VVOS gaining more in the future.

    Conclusion

    The stock of Vivos Therapeutics (VVOS) gained following the news of its success in the study conducted. The new results are promising, and the company hopes that it will help them regain the stock value once they go commercial with the treatment. The treatment targets millions of patients in the US and across the globe and will increase its market share.